Product Description
Dual GH Pathway Research Peptide Formulation
CJC-1295 (no DAC) and Ipamorelin are combined in a synergistic peptide formulation developed for laboratory research examining endogenous growth hormone (GH) signaling. This pairing brings together a GHRH analogue and a growth hormone–releasing peptide (GHRP), enabling investigation of dual-pathway modulation of GH secretion frequency and amplitude in non-clinical models.
Key Research Areas
🧬
Pituitary GH axis signaling and pulsatile growth hormone release dynamics
💪
Protein synthesis and anabolic signaling research models
⚡
Lipid metabolism and lipolysis pathway investigations
🌙
Sleep-related endocrine patterns and recovery signaling studies
🔬
Connective tissue and muscle regeneration research frameworks
This formulation is frequently utilized as a comprehensive research tool for studying endocrine regulation, performance-recovery mechanisms, and regenerative signaling pathways within controlled laboratory settings.
Intended Use
📦 Format: Lyophilized powder (CJC-1295 No DAC 5mg + Ipamorelin 5mg)
⚠️ Use: For laboratory research use only. Not for human or veterinary use.
Why Researchers Choose This Formulation
🔗
Dual GH pathway coverage supports investigation of both GHRH-mediated and GHRP-mediated signaling rather than single-pathway models alone.
🧪
Broad endocrine and recovery relevance makes it useful for pulsatile GH release, anabolic signaling, recovery, and lipolysis-focused research.
📈
Strong performance-research utility offers a focused framework for studying integrated endocrine regulation and regenerative pathway interaction.
Product Notes
✅ Research category: GH-axis and endocrine signaling
✅ Study context: Laboratory and non-clinical research models
✅ Compound focus: CJC-1295 (No DAC) and Ipamorelin dual-pathway interaction